R esearch into the effectiveness of HMOs among Medicare patients aged 65 or more is important since the number of Medicare beneficiaries enrolled in HMOs has grown from 3.6 million in 1995 to 5.6 million in 1997, 1, 2 and leading Medicare reform proposals would expand the use of managed care. Although managed care potentially can improve health care quality by facilitating prevention, screening and treatment interventions, recently there has been growing concern about quality of care provided by HMOs. Breast cancer is a significant disease, for which data are available to research the performance of HMOs among Medicare patients. Among U.S. women aged 65 or more, breast cancer is the most common site of new invasive cancers and the second most common cause of cancer mortality, with an estimated 87,500 new cases and 26,000 deaths in 1996. 3, 4 Further, early detection and treatment of breast is associated with improved survival. In California (current study site) breast cancer mortality among older women fell about 9% from 1988 to 1996, 5 owing in part to increased use of screening mammography and earlier stage at diagnosis.
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Major clinical trials in the 1980s demonstrated that survival was similar for early stage breast cancer patients treated with breast-conserving surgery (BCS) or mastectomy. 9±11 Subsequently the 1990 NIH Consensus Conference 12 recommended BCS plus radiation therapy as preferable treatment for the majority of Stage I or II breast cancers without reference to age of the patient. The proportion of early stage breast cancers treated with BCS among older California women increased from 28% in 1988 to 43% in 1992. 7 The present multivariate study of breast cancer patients aged 65 and older residing in northern California investigates quality of breast cancer care by examining the relationship of six types of health insurance to three outcomes: 1) stage at diagnosis; 2) treatment modality selected; and 3) survival. The study also considers breast cancer outcomes relative to hospital type while adjusting for other factors known to be associated with these outcomes (age, ethnicity, education, neighborhood class, and time period). This paper explores the following hypotheses: 1) Among Medicare beneficiaries with breast cancer, the odds of early stage diagnosis differ between those with private insurance (private FFS, group-model HMO, non-group-model HMO) and those without, and within the private insurance group stage at diagnosis varies by insurance type; 2) Among Medicare patients diagnosed at an early stage, use of BCS plus radiation varies over time and with hospital type; and 3) Among Medicare beneficiaries having early stage breast cancer, there are insurance-related differences in survival, with better outcomes associated with private insurance.
In testing these hypotheses the current study extends and improves upon existing literature in several ways. First, few prior studies of breast cancer stage at diagnosis among Medicare beneficiaries compared HMO and FFS patients, and none employed the detailed categorization of insurance coverage found here. 15, 18, 23, 24 In an earlier study, Riley et al. 18 used a heterogeneous FFS group, including Medicare patients with private FFS supplemental insurance as well as those having only Medicare and those with Medicaid; but this FFS grouping biases inferences related to detection and treatment in favor of HMOs. In addition, the current study distinguishes between group and non-group model HMOs, which is important since they differ in physician culture, organization, and financial incentives. While much early research involving HMO treatment outcomes among older females is based on data from group model plans, growth in HMO enrollment in the 1980s and 1990s was almost entirely due to non-group model plans. 25 Two previous investigators 22, 23 considered the relationship between insurance coverage and breast cancer treatment among Medicare patients (again, using the catch-all FFS category), lacking controls for hospital type. Conversely, many others considered the relationship between hospital characteristics and breast cancer treatment for women aged 65 or more, without accounting for differences in insurance coverage among patients.
17,19±
21,26±29 The present study improves upon most of this literature by including both insurance and hospital type, using a hospital typology which includes a category for HMO-owned hospitals.
A final advantage of this study relative to earlier research is the time period (1987±1993) to which the current data pertain, providing new HMO/private FFS comparisons regarding diagnosis and survival among older women. The timing of the present study is also well-suited for studying breast cancer outcomes, as diagnosis of study subjects encompasses both the NIH Consensus Conference year and inception of Medicare coverage for biennial mammograms (1990).
SUBJECTS AND METHODS

Study Subjects
Patients for this study were identified through the Cancer Surveillance Program, Region 3 (Sacramento, Calif), one of ten population-based regional registries in the statewide California Cancer Registry. All subjects were residents of the thirteen county region including Alpine, Amador, Calaveras, El Dorado, Nevada, Placer, Sacramento, San Joaquin, Sierra, Solano, Sutter, Yolo, and Yuba counties, a mixture of urban and rural areas in northern California with an estimated total population of 2.6 million in 1990. The Region 3 registry includes case reports for all resident cancer patients seen in hospitals and clinics in the 13-county region. In addition, case reports from other regions and from physicians' offices and other facilities within the region ensure virtually 100% ascertainment of incident cancer cases among regional residents. 30 Using data from a single geographic area has both pros and cons, although the former significantly outweigh the latter. On the positive side, it reduces the possibility that geographic differences in practice and treatment patterns related to differences in physician training and other factors will confound the relationship between insurance status and cancer-related outcomes. This is particularly important for the current study since there is tremendous variation in HMO penetration across the country.
2 By focusing on northern California, this study examines a mature managed care market that is indicative of the direction in which one might expect other managed care markets to evolve. The obvious limitation of this approach is that, to the extent that northern California is unique relative to the rest of the country in HMO practices and policies, the results may not generalize to all other settings. Study subjects were women aged 65 or greater diagnosed 1987±1993 with invasive breast cancer (ICDO diagnostic codes C50.0 through C50.9), 31 having no known prior cancer at any site and receiving all or part of their first course of treatment at the reporting hospital. Because of the cost of obtaining insurance data, the analysis was conducted on a sample of available patients. All nonHispanic African American (African American), Hispanic, and non-Hispanic Asian/other (Asian) patients were included to ensure sufficient cell sizes for estimating ethnic differences in stage, treatment, and mortality. In addition, a 28% random sample of non-Hispanic Whites (Whites) was drawn. Excluded from the study were 2 patients diagnosed in hospitals outside northern California, 34 reported by non-hospital sources, 20 not treated at the reporting hospital, and 137 whose tumor could not be staged due to incomplete information. The total sample size was 1,146; for some analyses the sample was smaller (explained below). The first study outcome, stage at diagnosis, was determined from information on tumor size, nodal involvement, and metastases, following guidelines from the American Joint Commission on Cancer. 32, 33 Stage I tumors are confined to the breast and 2 cm in diameter; Stage II tumors either are >2 cm or involve moveable ipsilateral axillary nodes or both. Stage III and IV tumors are more extensive, involving fixed axillary nodes, direct extension to the chest wall or skin, or distant metastases. Treatment outcomes considered were: 1) breastconserving surgery (BCS) without radiation; 2) breastconserving surgery with radiation (BCS+); 3) mastectomy; or 4) other/ unknown. BCS surgeries include nipple resection, lumpectomy, excisional biopsy, wedge resection, quadrantectomy, segmental mastectomy, tylectomy, and partial mastectomy. The mastectomy category included total (or simple), modified radical, and radical mastectomy.
For survival analyses, follow-up information (vital status, date of death or last contact) through December 1996 was obtained from hospital tumor registrar reports, and through linkage with annual California mortality files. For those not known to have died, date of last contact was also updated by linking with files from the California Department of Motor Vehicles. The mean follow-up time from diagnosis date was 51.2 months. At 30, 60, and 90 months after diagnosis, respectively, 79%, 39%, and 11% of Stage I and II patients were at risk of dying.
The cancer registry provided standard data items for this study, including age at diagnosis, ethnicity, tumor data, type of hospital, and treatment variables. No data were available from this source regarding the main independent variable of interest in this study: health insurance status at diagnosis. This information was determined from hospital records for 98% of patients. Study subjects were assumed to have their current insurance in effect during the year preceding diagnosis, when screening might detect the disease. The likelihood of switching health plans after diagnosis is estimated to be minimal (Strombom B, Buchmueller T, Feldstein P.`S witching costs, price sensitivity, and health plans,'' unpublished, May 2000). Insurance status was coded as follows: 1) Medicare alone; 2) Medicare/private FFS; 3) Medicare/Medicaid; 4) Medicare/group model HMO; 5) Medicare/non-group model HMO; and 6) other (including unknown). The group HMO category consists of one plan, which is one of the largest both in the region and nationally. A total of 9 different health plans are represented in the non-group HMO category, and the largest of these accounts for 74% of the observations in this category. Due to consolidation in the industry, the number of distinct HMOs in the dataset declines over time Ð by 1993 five non-group HMOs were represented. It is important to determine whether HMOs place greater emphasis on early diagnosis than FFS plans and whether certain types of HMOs (profit/non-profit and group/nongroup models) are more effective in this regard. Thus, the ability to differentiate between so many types of insurance coverage is a key factor which distinguishes this analysis from previous studies.
Although the cancer registry has no information on patient socioeconomic status (SES), which may affect on various outcomes in this study. 6 ,34±41 there is information on each patient's census block-group at the time of diagnosis. Thus, two block-group variables from the U.S. 1990 census were included as controls for SES: percent blue collar, and percent age 25 or over having a college degree. 35, 42 Based on the percentage of block-group workers employed in working class occupations, a patient's neighborhood class was designated as blue collar ( 66%) or non-blue collar. 42 The observed range of educational levels was divided into tertiles, yielding a designation of least, moderately, or most educated for each patient. To study the relationship between hospital type and treatment selected, hospitals providing data for this study were classified as follows: large community (n = 13, 270+ licensed beds), medium community (n = 10, 170 to 269 beds), moderately small community (n = 17, 95 to 169 beds), very small community (n = 8, 95 beds), rural (n = 7), teaching (n = 8), and HMO-owned hospitals (n = 10).
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Analysis
Statistics for this study were computed with SAS procedures. 45, 46 The 1 2 test was used to evaluate differences in the distribution of categorical variables (ethnicity, education, neighborhood class, stage at diagnosis) by type of health insurance; the Kruskal±Wallis analysis of variance by ranks was used to test for differences in age by insurance type. In the model-building process important measurable risk factors were first identified, and the best fitting multivariate regression model containing these variables was determined. Two-factor interactions significant at the .05 level were included. Logistic regression models were tested for goodness-of-fit; in each case there was good agreement between observed values and those predicted from the models. 47 The analysis began with an examination of the relationship between patient insurance status and stage at diagnosis of breast cancer, controlling for differences in age, ethnicity, and SES measures. The basic model is given by:
(1) Stage = F (insurance, age, ethnicity, education, neighborhood class).
The outcome variable, or stage at diagnosis, was estimated by a polytomous response logistic regression model. 47, 48 The model compared patients with Stage I, Stage II tumors 2.5 cm, and Stages III±IV, respectively, against the baseline group (patients with Stage II tumors >2.5 cm). This is similar to a series of dichotomous response logistic regressions, each one estimating the probability of diagnosis at a specific stage versus diagnosis at the baseline (e.g., Stage I vs Stage II with tumor >2.5 cm). For a specific outcome (stage), an odds ratio greater than 1.0 for a particular level of independent variable denotes increased likelihood of diagnosis at that stage compared to the reference level.
The second outcome examined was treatment selected, which was measured as a dichotomous variable Ð BCS+ vs mastectomy. The analysis was limited to patients diagnosed at Stage I or II, as BCS+ is recommended treatment for early stage breast cancer. 12 The independent variables of primary interest are insurance coverage and hospital type. The hospital effects were allowed to vary over time to account for possible differences in the diffusion of recommended practices. The treatment model is given by: Survival was estimated by Cox proportional hazards multivariate regression models for censored survival data. 49, 50 Since patients seen at HMO-owned hospitals had only group model HMO insurance and insurance type was the significant factor in this analysis, hospital type was set equal to zero for these patients. In estimating z Education (based on average educational level of patient's 1990 census block group) differs significantly by type of insurance ( P < .001).
x Neighborhood class (based on % blue collar workers in patient's 1990 census block group) differs significantly by type of insurance ( P = .006).
The line for Unknown Neighborhood Class is identical to the line for Unknown Education. This is due to the fact that census tract was unknown for 32 individuals out of the 1,146, and neither Neighborhood Class nor Education could be estimated for these individuals. k Median age differs significantly by type of insurance (Kruskal-Wallis analysis of variance by ranks, P < .001). { Interquartile range is interval from 25 th to 75 th percentile (middle 50% of observations). Stage at diagnosis differs significantly by type of insurance ( P = .001).
Medicaid (n = 174)
Other Insurance (Including Unknown)* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * (n = 61) breast cancer mortality, those dying of other causes were censored at date of death. In addition, Kaplan±Meier estimates of survival 51 by time since diagnosis were calculated; the log-rank test 52 was used to assess differences by insurance type. Table 1 reports summary statistics on variables used in this study, by insurance category at diagnosis. Overall, 28% of study subjects were in HMOs. The unadjusted distribution for each variable presented (ethnicity, education, neighborhood class, treatment hospital, and stage at diagnosis) differed significantly among patients by type of insurance. The percentage of African Americans and the percentage of least educated among Medicaid and Medicare alone enrollees differs significantly from private FFS enrollees. This dissimilarity strongly suggests the inadvisability of combining these categories (Medicaid, Medicare alone, and private FFS) in comparing outcomes between HMO and FFS enrollees.
RESULTS
The majority of patients in each insurance type were treated at either large or medium/moderately small community hospitals, except for group model HMO patients, who were treated exclusively at HMO-owned hospitals (Table 1) . This points up a major distinction between group model and non-group model HMO study subjects. Of all insurance types, Medicaid patients were least likely to have Stage I tumors (OR, 0.50; P = .005). This is consistent with earlier study findings that Medicaid patients are less likely than those with private insurance to have recent mammograms. 53±55 Because of the nonexperimental nature of the current dataset and the limited number of patient-level control variables, results attributed to the insurance variable may be partially due to differences in unmeasured patient characteristics correlated with insurance coverage. Indeed, odds ratios associated with the insurance variable should not be interpreted as causal effects. Whatever the explanation, the large difference in Stage I diagnosis between Medicare patients with private FFS insurance and those with Medicaid argue against measuring HMO performance according to comparisons with a catch-all FFS category. To test for the bias associated with this empirical approach, the stage model was re-estimated with all three types of FFS insurance combined into a single category. Key results from this model, which is similar to that of Potosky et al., 22 are reported in the top panel of Table 3 . Not surprisingly, this specification implies larger and more significant HMO-FFS differences than the specification preferred in the current study.
Stage
Treatment Figure 1 describes unadjusted data for treatment selected for Stage I /II patients, indicating variation by both type of hospital and time period. Patients at HMOowned hospitals were most likely to be treated with BCS+ (32% in the two time periods combined). Overall, 8% of Stage I /II patients were treated with BCS alone (no radiation). Table 4 presents results from the logistic regression model for treatment selection among Stage I/II patients, showing odds ratios for treatment with BCS+ (vs mastectomy), by hospital type and time period, and by insurance type. Contrary to unadjusted descriptive statistics in Figure 1 , results in Table 4 indicate that in the 1987± 1990 time period only medium/moderately small community hospitals were significantly more likely to treat with BCS+ than large community hospitals (reference group) (OR, 2.60; P = .006), after adjustment for differences due to stage, insurance, age, ethnicity, and SES variables. By 1991±1993 the significant three-fold increase in likelihood of BCS+ at large community hospitals is most noteworthy (OR, 3.47; P < .001), but increased use of BCS+ is evident at all types of hospitals.
No model results are presented for Stage I/II patients receiving BCS without radiation, due to the small number of patients receiving this treatment (n = 86). However, age was observed to be a factor related to choice of BCS without ). radiation; patients aged 80 or more at diagnosis were nearly eight times as likely as those less than age 80 to receive BCS without radiation as opposed to BCS+ or mastectomy (1 2 , 130.7; df, 2; P < .001). Generally, the relationship between insurance type and treatment selected was not significant after adjustment for differences in hospital type and other variables considered. The one exception Ð women with Medicaid Ð were more likely than those with private FFS coverage to receive BCS+ (OR, 1.48; P = .04).
Survival
During the ten-year follow-up period there were 393 deaths among study subjects, 171 of these due to breast cancer. Among Stage I and II patients, 104 of the 291 deaths were due to breast cancer. Figure 2 , presenting unadjusted survival for Stage I and II patients by type of insurance, suggests that there are significant differences in all-cause mortality among Medicare patients enrolled in the various health plans (P < .001). Table 5 gives results from the multivariate Cox proportional hazards regression model for both all cause and breast cancer mortality, by type of insurance, stage at diagnosis, treatment, and ethnicity. Each mortality risk ratio (RR) was also adjusted for differences in age, hospital type, and SES variables. An RR greater than 1.00 implies increased risk of dying, relative to the reference category. As expected, both all-cause and breast cancer mortality were significantly related to stage at diagnosis and treatment.
Mortality risks did not differ significantly among patients with private FFS, group model HMO, and nongroup model HMO insurance. However, patients with Medicare alone or with Medicaid had significantly higher all-cause mortality (RR, 1.54, P = .016; RR, 1.48, P = .02, respectively), and those with Medicare alone had significantly higher breast cancer mortality (RR, 2.36; P = .007) than the private FFS-insured.
In view of the worse all-cause survival of patients with Medicaid compared to private FFS-insured, current study data were used to re-estimate all-cause survival to determine the bias introduced by combining Medicare patients with the three types of FFS insurance (Medicaid, Medicare alone, and private FFS) into a single category. Results from this model, similar to that of Potosky et al. 22 and given in the bottom panel of Table 3 , imply greater and more significant HMO all-cause survival advantage than the preferred result in the current study. 
DISCUSSION
Earlier research suggested that elderly breast cancer patients in HMOs have a significant advantage over those in FFS Medicare in terms of detection, treatment and survival. The findings of this study suggest an important qualification to this conclusion: among Medicare patients with any type of private insurance, there are no significant differences between those in HMOs and those with FFS supplemental insurance. However, the study reports pronounced differences between Medicare patients with and without private insurance, and this contrast appears to have driven the HMO-FFS differences identified by previous researchers.
This finding has important policy implications. During the current study period, vigorous competition among HMOs for Medicare beneficiaries meant that in many areas, including the present study locale, beneficiaries could obtain HMO coverage at minimal out-of-pocket cost. As a result HMOs were very attractive to Medicare beneficiaries of moderate means who found private supplemental insurance [FFS] prohibitively expensive. More recently, reductions in federal payments to HMOs have caused a number of plans to exit the Medicare program, and others to increase premiums to beneficiaries. The similarity in breast cancer outcomes between Medicare HMOs and Medicare/private FFS insurance suggests that patients able to move from the former to the latter will not suffer in terms of the cancer outcomes studied here. However, since HMO coverage does appear to improve outcomes relative to Medicare alone, the contraction of managed care options may have more negative consequences for patients unable to afford, or too sick to qualify for, private FFS supplemental insurance.
Results of this paper regarding the relationship between hospital type and breast cancer outcomes are consistent with a similar study among women under age 65 in northern California. 56 But they differ from an earlier study 17 among southern California women of all ages with localized or regional breast cancer, particularly the finding that patients at HMO-owned hospitals were less likely to receive BCS+ than patients at other types of hospitals. These results highlight the fact that delivery system differences can vary considerably across regions. While this study adds to knowledge of the relationships among insurance coverage, delivery system type, and cancer outcomes, a number of limitations should be acknowledged. As with all studies of this type, the present analysis is based on observational (i.e., non-experimental) data, making it impossible to fully account for differences in patient characteristics that affect both selection into the different insurance categories and the outcome variables. This complicates the interpretation of current results.
Another similarity between this study and others in the literature is the limited geographic scope. An important advantage of focusing on one region is that it allows for collection of additional insurance data. Also, present study comparisons of HMO and FFS patients are not confounded by regional differences in practice patterns. However, an obvious limitation is that these results reflect the behavior of a relatively small number of health plans and hospitals. To the extent that these organizations are unique, current study results may not generalize widely. The fact that the focus is on a region that is both large in size and important with respect to the evolution of its health care market mitigates, but does not eliminate, this shortcoming. Similar research in other geographic regions would be very useful for better understanding of the relationship between financing and delivery system characteristics and treatment outcomes.
No reliable information was available for this study regarding the use of systemic adjuvant therapy. The likelihood that this will bias survival results for Stage I and II patients is believed to be minimal. Comorbidity data were also absent, since the dataset available for this study contained no personal identifiers for individual patients and could not be linked to either hospital discharge files or Medicare claims files which are common sources of comorbidity information. For this reason survival results in this study should be interpreted with caution. However, comorbidity adjustments are believed to have minimal effect on mortality risk ratios associated with insurance Ð after adjustments have been made for age, ethnicity, education, neighborhood class, hospital type, stage, and treatment Ð as a previous study of Medicare patients with breast cancer suggests. 22 Secondly, women aged 80 or more with Stage I breast cancer and two or more comorbid conditions reportedly are likely to receive BCS, and their probability of receiving radiation therapy tends to decline rapidly with age. 21 The significant all-cause mortality associated with BCS alone in Table 5 may in part be a result of the presence of comorbid conditions among the 83 women receiving BCS alone, approximately two thirds of whom were aged 80 or more. In the future better data will allow these limitations to be addressed. Despite its limitations this study clarifies the relationship of insurance type and hospital type to breast cancer outcomes among Medicare patients. The need for greater use of BCS+ among early stage Medicare patients suggests that physician education on the NIH-recommended treatment methods continued to require attention of the medical profession after the early 1990s. While rates of BCS+ use in the current study region are expected to have increased in the mid-to late-1990s, large variation by hospital type is likely to persist. 
